Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Utilization patterns and projected demand of antiretroviral drugs in low- and middle-income countries.

Renaud-Théry F, Avila-Figueroa C, Stover J, Thierry S, Vitoria M, Habiyambere V, Souteyrand Y.

AIDS Res Treat. 2011;2011:749041. doi: 10.1155/2011/749041. Epub 2011 Mar 24.

2.

Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens.

Renaud-Théry F, Nguimfack BD, Vitoria M, Lee E, Graaff P, Samb B, Perriëns J.

AIDS. 2007 Jul;21 Suppl 4:S89-95.

PMID:
17620758
3.

Forecast of demand for antiretroviral drugs in low and middle-income countries: 2007-2008.

Galárraga O, O'Brien ME, Gutiérrez JP, Renaud-Théry F, Nguimfack BD, Beusenberg M, Waldman K, Soni A, Bertozzi SM, Greener R.

AIDS. 2007 Jul;21 Suppl 4:S97-103.

PMID:
17620759
4.

Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.

Bendavid E, Grant P, Talbot A, Owens DK, Zolopa A.

AIDS. 2011 Jan 14;25(2):211-20. doi: 10.1097/QAD.0b013e328340fdf8.

5.

Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.

Siegfried NL, Van Deventer PJ, Mahomed FA, Rutherford GW.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD004535. Review.

PMID:
16625606
6.

A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.

Pinheiro Edos S, Antunes OA, Fortunak JM.

Antiviral Res. 2008 Sep;79(3):143-65. doi: 10.1016/j.antiviral.2008.05.001. Epub 2008 Jun 2. Review.

PMID:
18571246
7.

Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.

Nunn AS, Fonseca EM, Bastos FI, Gruskin S, Salomon JA.

PLoS Med. 2007 Nov 13;4(11):e305.

8.

Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho.

Jouquet G, Bygrave H, Kranzer K, Ford N, Gadot L, Lee J, Hilderbrand K, Goemaere E, Vlahakis N, Trivino L, Makakole L, Cleary S.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):e68-74. doi: 10.1097/QAI.0b013e31822a9f8d.

PMID:
21765366
9.

Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.

Di Biagio A, Prinapori R, Giannarelli D, Maggiolo F, Di Giambenedetto S, Borghi V, Penco G, Cicconi P, Francisci D, Sterrantino G, Zoncada A, Monno L, Capetti A, Giacometti A; ARCA Collaborative Group.

J Antimicrob Chemother. 2013 Jan;68(1):200-5. doi: 10.1093/jac/dks339. Epub 2012 Aug 21.

PMID:
22915463
10.

Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.

Tang MW, Rhee SY, Bertagnolio S, Ford N, Holmes S, Sigaloff KC, Hamers RL, de Wit TF, Fleury HJ, Kanki PJ, Ruxrungtham K, Hawkins CA, Wallis CL, Stevens W, van Zyl GU, Manosuthi W, Hosseinipour MC, Ngo-Giang-Huong N, Belec L, Peeters M, Aghokeng A, Bunupuradah T, Burda S, Cane P, Cappelli G, Charpentier C, Dagnra AY, Deshpande AK, El-Katib Z, Eshleman SH, Fokam J, Gody JC, Katzenstein D, Koyalta DD, Kumwenda JJ, Lallemant M, Lynen L, Marconi VC, Margot NA, Moussa S, Ndung'u T, Nyambi PN, Orrell C, Schapiro JM, Schuurman R, Sirivichayakul S, Smith D, Zolfo M, Jordan MR, Shafer RW.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S70-7. doi: 10.1093/infdis/jit114.

11.

An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China.

Li T, Guo F, Li Y, Zhang C, Han Y, Lye W, He Y, Lu H, Xie J, Huang A, Li Y, Tang X, Wang H, Zhang T, Gao G, Lei J, Zhang X, Wu X, Sun Y, Bai J, Luo L, Wang H.

Chin Med J (Engl). 2014;127(1):59-65.

PMID:
24384425
12.

A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.

Phidisa II Writing Team for Project Phidisa, Ratsela A, Polis M, Dhlomo S, Emery S, Grandits G, Khabo P, Khanyile T, Komati S, Neaton JD, Naidoo LC, Magongoa D, Qolohle D.

J Infect Dis. 2010 Nov 15;202(10):1529-37. doi: 10.1086/656718. Epub 2010 Oct 13.

13.

Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.

Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, Rezk NL, Bridges AS, Stewart PW, Cohen MS, Kashuba AD.

AIDS. 2007 Sep 12;21(14):1899-907.

14.

Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets.

Waning B, Kyle M, Diedrichsen E, Soucy L, Hochstadt J, Bärnighausen T, Moon S.

Global Health. 2010 May 25;6:9. doi: 10.1186/1744-8603-6-9.

15.

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK; Study 934 Group.

N Engl J Med. 2006 Jan 19;354(3):251-60.

16.

Antiretroviral therapies in women after single-dose nevirapine exposure.

Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, Sawe F, Asmelash A, Hosseinipour MC, Mohapi L, Stringer E, Mngqibisa R, Siika A, Atwine D, Hakim J, Shaffer D, Kanyama C, Wools-Kaloustian K, Salata RA, Hogg E, Alston-Smith B, Walawander A, Purcelle-Smith E, Eshleman S, Rooney J, Rahim S, Mellors JW, Schooley RT, Currier JS; OCTANE A5208 Study Team.

N Engl J Med. 2010 Oct 14;363(16):1499-509. doi: 10.1056/NEJMoa0906626.

17.

Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.

van Vonderen MG, van Agtmael MA, Hassink EA, Milinkovic A, Brinkman K, Geerlings SE, Ristola M, van Eeden A, Danner SA, Reiss P; MEDICLAS study group.

PLoS One. 2009 May 21;4(5):e5647. doi: 10.1371/journal.pone.0005647.

18.

Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014-2018.

Hill A, Hill T, Jose S, Pozniak A.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19497. doi: 10.7448/IAS.17.4.19497. eCollection 2014.

19.

Optimizing antiretroviral product selection: a sample approach to improving patient outcomes, saving money, and scaling-up health services in developing countries.

Amole CD, Brisebois C, Essajee S, Koehler E, Levin AD, Moore MC, Brown Ripin DH, Sickler JJ, Singh IR.

J Acquir Immune Defic Syndr. 2011 Aug;57 Suppl 2:S100-3. doi: 10.1097/QAI.0b013e318220f016.

PMID:
21857290
20.

Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India.

Bender MA, Kumarasamy N, Mayer KH, Wang B, Walensky RP, Flanigan T, Schackman BR, Scott CA, Lu Z, Freedberg KA.

Clin Infect Dis. 2010 Feb 1;50(3):416-25. doi: 10.1086/649884.

Supplemental Content

Support Center